Top Page
Stemcell United Ltd.
(Sydney:BP8)
Stemcell United Ltd. (BP8) vs. iShares MSCI Australia ETF (EWA)
Stemcell United Ltd. Business Overview & Revenue Model
Stemcell United Ltd. Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 352.38K | 109.97K | 339.00 | 14.35M | 8.50M |
| Gross Profit | -678.01K | 18.27K | 339.00 | 2.29M | 1.54M |
| EBITDA | -1.45M | -1.76M | -2.49M | -2.49M | -2.41M |
| Net Income | -1.49M | -2.27M | -4.32M | -3.54M | -3.13M |
Balance Sheet | |||||
| Total Assets | 541.00K | 691.84K | 2.10M | 7.16M | 10.11M |
| Cash, Cash Equivalents and Short-Term Investments | 152.74K | 134.82K | 1.14M | 685.56K | 5.26M |
| Total Debt | 0.00 | 508.64K | 0.00 | 1.30M | 1.76M |
| Total Liabilities | 2.01M | 1.97M | 1.19M | 2.44M | 3.83M |
| Stockholders Equity | -1.45M | -966.82K | 530.13K | 3.20M | 5.26M |
Cash Flow | |||||
| Free Cash Flow | -932.18K | -1.26M | -1.49M | -4.93M | -1.78M |
| Operating Cash Flow | -929.81K | 0.00 | 0.00 | 0.00 | 0.00 |
| Investing Cash Flow | -2.37K | 185.33K | 6.29K | -914.21K | -418.04K |
| Financing Cash Flow | 962.99K | 697.04K | 1.38M | 281.27K | 6.25M |
Stemcell United Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$11.02M | -1.00 | -218.76% | ― | ― | ― | |
44 Neutral | AU$4.71M | -0.76 | 95.35% | ― | ― | ― | |
43 Neutral | AU$3.94M | -0.33 | 346.27% | ― | 5.52% | 49.25% | |
43 Neutral | AU$9.32M | -1.61 | 142.99% | ― | -47.02% | 94.37% | |
40 Underperform | AU$2.17M | -4.31 | -32.19% | ― | ― | 46.43% | |
37 Underperform | AU$10.20M | -0.48 | 1068.18% | ― | ― | 31.87% |
Stemcell United Ltd. Corporate Events
BPH Global Ltd. has expanded its seaweed biomass research program to pursue renewable biofuel production alongside its existing nutraceutical focus. By fermenting seaweed, the company already produces biohydrogen and biomethane as by-products and plans to scale up biogas capture as these fermentation activities move toward commercial deployment.
The company is also assessing hydrothermal liquefaction to convert wet seaweed directly into biocrude, a crude-like renewable oil that could feed into energy, transport and potentially sustainable aviation fuel markets. The R&D program will optimise seaweed species selection, fermentation conditions and HTL processing to maximise fuel yields, positioning marine biomass as a low-carbon alternative to land-based biofuel feedstocks and potentially strengthening BPH Global’s role in emerging hydrogen and liquid biofuel supply chains.
The initiative underscores the environmental benefits of seaweed cultivation, which does not use arable land, freshwater or heavy fertiliser inputs and absorbs carbon dioxide during growth. If successful, the program could enhance the company’s ESG profile and open new commercial revenue streams in low-carbon energy, while aligning with global investment trends favouring scalable biofuel and hydrogen solutions that can partially replace fossil fuels.
The most recent analyst rating on (AU:BP8) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Stemcell United Ltd. stock, see the AU:BP8 Stock Forecast page.
BPH Global Limited has released an investor presentation outlining information about its seaweed biotechnology business and its positioning as an emerging player in this niche sector. The document emphasises that it is purely informational, does not constitute an offer or investment advice, and that recipients must conduct their own due diligence when assessing any potential investment.
The company stresses that no representation or warranty is given regarding the accuracy or completeness of the information provided, and that the material is preliminary and subject to change. It also notes that distribution of the presentation may be restricted by law in certain jurisdictions and directs investors to consider associated risks, underlining the cautious and compliance-focused nature of the communication.
The most recent analyst rating on (AU:BP8) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Stemcell United Ltd. stock, see the AU:BP8 Stock Forecast page.
BPH Global Ltd, an ASX-listed seaweed trader operating out of Makassar in Indonesia, sources product from local coastal farmers to supply domestic and export markets, including customers across Asia. The company is building an independent trading platform aimed at scaling volumes and deepening relationships with its farmer network while supporting long-term growth in the seaweed supply chain.
For its ninth trading month, covering 15 January to 14 February 2026, BPH Global reported gross sales of IDR 2.47 billion (about A$205,933), bringing nine-month aggregate sales to approximately A$2.36 million despite challenging seasonal conditions. Peak rainy season in Makassar and a customary slowdown ahead of Chinese New Year constrained harvest volumes and temporarily softened purchasing, but management reports stable customer relationships and intact underlying demand across domestic and export channels.
The company completed a A$1 million share placement during the period, allocating around A$600,000 specifically to its Indonesian seaweed operations to fund increased purchases from Makassar-based farmers. This capital injection materially improves working capital, enhancing BPH Global’s capacity to buy larger volumes as weather conditions improve, deepen engagement with farmer networks, and respond more flexibly to customer demand as it scales its trading platform.
Looking ahead, BPH Global expects trading conditions to improve as Makassar exits the peak rainy season and is positioning to expand independent trading volumes through its Makassar platform. Management views the strengthened balance sheet as strategically important for building a more resilient, higher-volume seaweed operation, with ongoing monthly sales updates to track progress and implications for suppliers and customers in the region.
The most recent analyst rating on (AU:BP8) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Stemcell United Ltd. stock, see the AU:BP8 Stock Forecast page.
Apertus Capital Pty Ltd has filed a notice that it has ceased to be a substantial shareholder in BPH Global Ltd following dilution arising from a share issue. The filing indicates that Apertus now has no voting power in BPH Global, and that there has been no change in its association status, signalling a reduced influence on the company’s shareholder base without any transactional consideration disclosed.
The notice, lodged under section 671B of the Corporations Act 2001, reflects regulatory requirements for transparency around movements in substantial holdings on the Australian market. For BPH Global investors, the change clarifies that Apertus no longer exerts substantial holder influence, while the dilution-driven shift underscores the impact that new share issues can have on existing investors’ percentage interests.
The most recent analyst rating on (AU:BP8) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Stemcell United Ltd. stock, see the AU:BP8 Stock Forecast page.
Stemcell United Ltd. has disclosed that ATIDIM Investments Pty Ltd and associated holder BPH Global Ltd have ceased to be substantial shareholders in the company following dilution from a new share issue. The notice indicates that ATIDIM’s voting power was reduced to zero due to the capital change, signalling a shift in the company’s ownership profile that may impact future governance dynamics and market perception of its shareholder stability.
The most recent analyst rating on (AU:BP8) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Stemcell United Ltd. stock, see the AU:BP8 Stock Forecast page.
BPH Global Ltd’s Indonesian subsidiary, PT BPH Global Indonesia, has signed a binding Memorandum of Understanding with Indonesia’s National Research and Innovation Agency (BRIN) under the government’s “BRIN Goes to Industries” initiative, a program aimed at accelerating the commercialisation of national research and strengthening strategic industrial capabilities. The agreement, which runs for an initial three-year term, establishes a framework for accessing and potentially licensing BRIN’s existing intellectual property in fucoidan extraction technology and undertaking co-development R&D, enabling BPH Global to advance into higher-margin, fucoidan-based anti-ageing and personal-care products and deepening its integration into Indonesia’s innovation ecosystem alongside a select group of industrial partners.
The most recent analyst rating on (AU:BP8) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Stemcell United Ltd. stock, see the AU:BP8 Stock Forecast page.
BPH Global Ltd has lodged a notice of a proposed securities issue with the ASX, outlining plans to issue up to 150 million new options as part of a placement or similar capital-raising mechanism. The options will carry an exercise price of $0.004 and a three-year expiry from the date of issue, with a proposed issue date of 8 May 2026, indicating the company is seeking additional funding flexibility that could lead to future equity dilution but may support its capital needs and strategic initiatives.
The most recent analyst rating on (AU:BP8) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Stemcell United Ltd. stock, see the AU:BP8 Stock Forecast page.
BPH Global Ltd, listed on the ASX under code BP8, is an Australia-registered company; the announcement does not specify its industry, products, or market focus. The company has notified the ASX of a proposed capital raising via the issue of up to 500 million new fully paid ordinary shares and 250 million options exercisable at $0.004 over three years, with the issue scheduled for 12 February 2026, a move that will significantly increase its capital base and potentially dilute existing shareholders while providing additional funding for its activities.
The most recent analyst rating on (AU:BP8) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Stemcell United Ltd. stock, see the AU:BP8 Stock Forecast page.
BPH Global has secured firm commitments for a $1 million strategic share placement at market price, introducing new long-term investors and bolstering its balance sheet as its Indonesian seaweed operations record their strongest and second-strongest monthly sales since launching in May 2025. The funds will be primarily directed to scaling up seaweed trading volumes and exports, with additional allocations to research and development and working capital, leveraging the company’s existing licensed infrastructure to reduce execution risk and support a targeted shift toward higher-margin revenue streams and disciplined growth in both its core trading and emerging biotechnology and functional nutrition segments.
The most recent analyst rating on (AU:BP8) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Stemcell United Ltd. stock, see the AU:BP8 Stock Forecast page.
BPH Global Ltd, listed on the ASX under the ticker BP8, has requested a trading halt in its securities as it prepares an announcement regarding a capital raising. Trading in BPH Global shares will be paused until either the start of normal trading on 5 February 2026 or the release of the capital-raising announcement, signalling that the company is undertaking a potentially significant funding move that could affect its capital structure and investor positioning once details are disclosed.
The most recent analyst rating on (AU:BP8) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Stemcell United Ltd. stock, see the AU:BP8 Stock Forecast page.
BPH Global Ltd has announced a change to its registered office address, relocating its corporate headquarters to Suite 303, 365 Little Collins Street in Melbourne, Victoria, effective 2 February 2026. The move represents an administrative update with no change to the company’s listed telephone contact details and has been formally approved by the board, indicating continuity in operations and stakeholder communication despite the change in office location.
The most recent analyst rating on (AU:BP8) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Stemcell United Ltd. stock, see the AU:BP8 Stock Forecast page.
BPH Global has reported its December quarter activities, highlighting completion of the second tranche of a capital raising of up to A$1.1 million through the issue of 550 million shares with attached options, following shareholder approval in November, and ending the period with cash of around A$0.598 million. Operationally, the group continued to consolidate and scale its Indonesian seaweed trading business, delivering record monthly sales in October–November, a rebound to near-record volumes in the subsequent month, strengthening customer relationships and sourcing capacity via its Makassar warehouse, and securing a key Indonesian seaweed export licence that enables direct international sales, underpinning a positive outlook for 2026.
The most recent analyst rating on (AU:BP8) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Stemcell United Ltd. stock, see the AU:BP8 Stock Forecast page.
BPH Global Ltd has reported significant assay results from riverbed soil samples collected at two freshwater sites in Malaysia’s Johor River, with measurable concentrations of copper, silver and selected rare earth elements, including lanthanum, yttrium and neodymium. The findings, generated under its Project 6–7 R&D program, confirm the presence of mineralised sediments adjacent to and downstream from a mining operation and support the company’s hypothesis that metals in the river system may be available for biological uptake by seaweed. While the company stresses it is not pursuing soil or sediment mining, these results pave the way for the next phase of work: cultivating Sesuvium portulacastrum in the Johor River to test its ability to bio-accumulate gold, silver and copper, potentially opening new avenues for value-added seaweed applications and strengthening BPH Global’s positioning in the intersection of aquaculture and resource recovery.
The most recent analyst rating on (AU:BP8) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Stemcell United Ltd. stock, see the AU:BP8 Stock Forecast page.
BPH Global Ltd has launched a low-risk research and development program to evaluate the use of non-export grade Eucheuma cottonii seaweed in animal feed and feed supplement applications, aiming to utilise biologically active material that falls outside export specifications. The initiative, which leverages existing Indonesian sourcing and operational infrastructure, will examine nutritional value, functional bioactive properties, potential methane-reduction effects, and processing methods, with the goal of improving raw material utilisation, reducing waste, enhancing margin resilience and supporting ESG objectives, without altering the company’s core seaweed trading and export business at this stage.
The most recent analyst rating on (AU:BP8) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Stemcell United Ltd. stock, see the AU:BP8 Stock Forecast page.
BPH Global Ltd has finalised an updated 2026–2027 R&D program under its “Project 6–7,” sharpening its focus on measuring, extracting and commercially recovering gold and silver from seaweed biomass. Following internal and external technical reviews, including input from its R&D consultant Gaia Mariculture and senior mining executives, the company is narrowing its previous broad minerals and rare earth elements work to concentrate on precious metals, informed by earlier assays that showed significant gold and silver accumulation in seaweed from the Johor Strait. The program will proceed via two parallel workstreams—ongoing harvesting and assay of seaweed from polluted and mineral-rich waters, including new sampling near a mining site in southern Malaysia, and in-house plus collaborative research on gold and silver extraction methods—aimed at accelerating commercialisation and potentially positioning BPH at the intersection of bio-based metal recovery and high‑value markets in commodities and advanced materials.
The most recent analyst rating on (AU:BP8) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Stemcell United Ltd. stock, see the AU:BP8 Stock Forecast page.
BPH Global reported gross revenue of IDR 1.88 billion (about A$171,000) for the December trading period, bringing total sales since commencing operations in mid-May to roughly A$1.77 million as the company continues to build its Indonesian seaweed platform. December’s revenue fell sharply from November’s record month but remained within the historical range of the business’s first half-year of trading, with management attributing the dip to the seasonal rainy season in South Sulawesi, which constrained supply and pushed farm-gate prices above levels that allowed profitable trading under existing contracts. The company stressed that underlying demand and customer relationships remain intact and said it is maintaining its focus on scaling operations, strengthening its supply chain and preparing for expanded export activity in 2026, positioning the business for longer-term growth despite short-term seasonal volatility.
BPH Global Ltd, listed on the ASX under ticker BP8, has reported a change in its issued capital structure following the expiry of certain options. The company announced that 1,000,000 BP8AA options, which were due to expire on various dates and at various exercise prices, have lapsed unexercised as of 18 December 2025, resulting in the cessation of these securities and a corresponding adjustment to the company’s potential diluted capital base.